Crinetics Pharmaceuticals to be Acquired by Vertex Pharmaceuticals in $10 Billion Deal

Paul, Weiss is advising Crinetics Pharmaceuticals, Inc., a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, on its all-cash $10 billion acquisition by Vertex Pharmaceuticals Incorporated. Under the agreement, Vertex will acquire Crinetics for $85 per share in cash. The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions and regulatory approvals.

The Paul, Weiss team is led by corporate partners Stan Richards and Krishna Veeraraghavan, and includes partners Nick Schwartz, Julie Ann Lamm and Daniel Yip; executive compensation partner Matthew Friestedt; litigation partners Geoffrey Chepiga and Tiana Voegelin; and antitrust partners Scott Sher and Lauren O’Brien.